<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sixty-two adults with <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (ALL) were treated with a modified BFM regimen </plain></SENT>
<SENT sid="1" pm="."><plain>Forty-two (70%) achieved complete remission (CR) </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-one percent of <z:hpo ids='HP_0000001'>all</z:hpo> evaluable patients and 32.4 percent of complete responders are in continuous complete remission (CCR) at a median follow-up of 41 months (range 24-81 months) </plain></SENT>
<SENT sid="3" pm="."><plain>Long-term survival was better in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T- ALL</z:e> (47.1%) when compared to precursor-<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B ALL</z:e> (4.8%) (P &lt; 0.04) </plain></SENT>
</text></document>